Zobrazeno 1 - 10
of 526
pro vyhledávání: '"Metastatic bladder cancer"'
Autor:
Anke Richters, Debbie G.J. Robbrecht, Richard P. Meijer, Antoine G. van der Heijden, Lambertus A.L.M. Kiemeney, Joan van den Bosch, Britt B.M. Suelmann, Berna C. Özdemir, Niven Mehra, Katja K.H. Aben
Publikováno v:
European Urology Open Science, Vol 59, Iss , Pp 50-54 (2024)
Since 2017, two immune checkpoint inhibitors (ICIs) have become the standard of care for the treatment of metastatic urothelial carcinoma in Europe: pembrolizumab as second-line therapy and avelumab as maintenance therapy. Our aim was to describe the
Externí odkaz:
https://doaj.org/article/4791160529b74281ba980260944fa5dc
Publikováno v:
IJU Case Reports, Vol 6, Iss 2, Pp 111-115 (2023)
Introduction Enfortumab vedotin is a novel drug for locally advanced or metastatic urothelial carcinoma, but it is associated with a high incidence of skin reactions (up to 47.0%). Case presentation A 71‐year‐old male was administered enfortumab
Externí odkaz:
https://doaj.org/article/61e313f11bbe4c93a8ac2f06da349c77
Autor:
Xiang Ren, Yiqun Tian, Zhixian Wang, Jing Wang, Xing Li, Yisheng Yin, Ruibao Chen, Ying Zhan, Xiaoyong Zeng
Publikováno v:
BMC Urology, Vol 22, Iss 1, Pp 1-7 (2022)
Abstract Background Combining immune checkpoint inhibitors with chemotherapy can synergistically improve antitumor activity and are generally well tolerated. Recently, the efficacy and safety of combination therapy has been demonstrated for many canc
Externí odkaz:
https://doaj.org/article/ccfe160267404960aad845347e0fbc79
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Egyptian Journal of Medical Human Genetics, Vol 23, Iss 1, Pp 1-12 (2022)
Abstract Background Urothelial cancer (UC) and prostate cancer (PCa) are the most common cancers among men with a high ratio of mortality in advanced-stages. The higher risk of these malignancies among men can be associated with higher carcinogens ex
Externí odkaz:
https://doaj.org/article/4514c7bc65a3458b9ce1115206f26aa0
Autor:
A. A. Gritskevich, A. Yu. Popov, I. G. Rusakov, E. K. Vozniy, V. A. Makarov, D. I. Gridnev, T. P. Baitman, S. V. Mishugin, I. V. Novikova, S. V. Khromova
Publikováno v:
Медицинский совет, Vol 0, Iss 9, Pp 95-103 (2022)
Urothelial cancer occupies a significant place in the routine practice of cancer treatment. Systemic antitumor treatment of patients with metastatic urothelial cancer in the first line is currently well studied, has its own standards, implemented in
Externí odkaz:
https://doaj.org/article/78a16071fc2a4c12b22247798a092ea2
Autor:
Tao Chen, Shuibo Shi, Ping Zheng, Xiangpeng Zhan, Ji Zhang, Yihe Li, Dongshui Li, Bin Fu, Luyao Chen
Publikováno v:
Frontiers in Surgery, Vol 9 (2023)
BackgroundMetastatic bladder cancer (MBC) is an incurable malignancy, which is prone to early death. We aimed to establish models to evaluating the risk of early death in patients with metastatic bladder cancerMethodsThe data of 1,264 patients with M
Externí odkaz:
https://doaj.org/article/73f5bca3220749af842e417c56e3f0a3
Autor:
Zhu-lei Tao, Wei Wu, Lin-chun Liang, Jin-feng Pan, Jian-zhou Cao, Xiao-long Jia, Li Fang, Qi Ma
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
This article described a patient with metastatic bladder cancer (mBC) who was successfully treated with nab-paclitaxel plus sintilimab. Localized muscle-invasive bladder cancer (MIBC) was discovered in a 56-year-old man who received radical cystectom
Externí odkaz:
https://doaj.org/article/e03c9754c2eb496587745806e0d2c3b1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Current Oncology, Vol 28, Iss 5, Pp 3812-3824 (2021)
Background: Real-world data on palliative systemic therapies (PST) in treating metastatic bladder cancer (mBC) is limited. This study investigates current trends in treating mBC with first- (1L) and second-line (2L) chemotherapy (CT) and immunotherap
Externí odkaz:
https://doaj.org/article/dd4ae11a7bae49ccab5897bb75afe73b